MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
two doctors, a man and a woman, examine an MRI image of the brain

FDA Decision On Tolebrutinib

MStranslate
January 12, 2026
Clinical Trials
A pair of hands around a crystal ball that has the year 2026 written inside it.

Multiple Sclerosis Research In 2026

MStranslate
January 5, 2026
Progressive MS, Remyelination, Treatments
ECTRIMS Congress 2025

Revisiting ECTRIMS Congress 2025

MStranslate
November 18, 2025
ECTRIMS, Podcasts, Research
The ECTRIMS Podcast

UPDATED: The ECTRIMS Podcast – Episode Library

MStranslate
September 10, 2025
ECTRIMS, Podcasts, Research
Patient Community Day

Patient Community Day at ECTRIMS 2025

MStranslate
July 22, 2025
ECTRIMS, Events, Research

Predicting Progression: Science Fiction or Reality?

MStranslate
April 9, 2019
Understanding Science
Yesterday, we posed a question on our Facebook page and asked people to use reactions to indicate how they would vote… Some people may be wondering if this was a purely philosophical exercise.  That...
exercise training

Exercise Barriers in Multiple Sclerosis: Falling

MStranslate
April 4, 2019
Exercise, Lifestyle, Movement Disorders, Rehabilitation, Research, Symptoms
It won’t come as a surprise to many that research has shown regular exercise can be especially important for people living with multiple sclerosis. In particular it has been shown to lead to improvements in...
Mavenclad

FDA Approves Second Drug For Active SPMS

MStranslate
April 1, 2019
Research, Treatments
Late last week, it was announced that Mavenclad (cladribine) received US FDA approval for the treatment of adults living with relapsing multiple sclerosis (MS). Importantly, this also includes people living...
employment

Research Into Employment Issues for PwMS

MStranslate
March 28, 2019
Lifestyle, Research
The following article was commissioned by MS Limited and has previously been published in their eNewsletter, Intouch.  We are revisiting this topic following the large response to our Facebook poll last...
siponimod

New Treatment Approved for Active SPMS

MStranslate
March 27, 2019
Research, Treatments
1 Comment
It was announced earlier today that Mayzent (siponimod) has received US FDA approval for the treatment of adults living with relapsing multiple sclerosis (MS).  Importantly, this also includes people living...
relationships

Relationships and Multiple Sclerosis

MStranslate
March 20, 2019
Lifestyle, Research
The following article was commissioned by MS Limited and has previously been published in their eNewsletter, Intouch.     As most of us have probably found out at some point in our...
Cocoa

Does a Cocoa a Day Keep MS Fatigue Away?

MStranslate
March 19, 2019
Fatigue, Research, Symptoms, Treatments
1 Comment
Research Summary: A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis Fatigue is one of the most...
Facebook Live

Taking The Opportunity To Talk

MStranslate
February 28, 2019
Community, Genetics, Q&A
Next week, we are holding another one of our Facebook Live Q&A sessions.  For this event, the theme will be genetics in multiple sclerosis.  It will provide us an opportunity to discuss a number of key...
HSCT

HSCT Trial Shows Positive Results for RRMS

MStranslate
February 19, 2019
Research, Stem Cells, Treatments
2 Comments
Research Summary: Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A...
CORe Unit

MS Treatments Delay Progressive Disease

MStranslate
February 12, 2019
Progressive MS, Research, Treatments
Research Summary: Association of Initial Disease-Modifying With Later Conversion to Secondary Progressive Multiple Sclerosis In mid-January, we had the good fortune of getting to break some major multiple...
  1. 7
  2. 8
  3. 9
  4. 10
  5. 11
  6. 12
  7. 13

Recent Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Jan    

Archives

Categories

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.